Disease · MONDO_0008558
Comparisons in its trials70
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 70
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Eltrombopag, Treatment + 1 Day vs Eltrombopag, >1 to 30 Days Post-Therapy: serious adverse events | 96 of 302 | 10 of 302 | 604 | NCT00351468 | Trial comparisons |
| Romiplostim (AMG 531) Cohort 1 vs Romiplostim (AMG 531) Cohort 2: Adverse Events | 162 of 168 | 215 of 239 | 407 | NCT00508820 | Trial comparisons |
| Romiplostim (AMG 531) Cohort 1 vs Romiplostim (AMG 531) Cohort 2: Platelet Response (Definition 2) | 160 of 168 | 220 of 239 | 407 | NCT00508820 | Trial comparisons |
| Romiplostim (AMG 531) Cohort 1 vs Romiplostim (AMG 531) Cohort 2: Platelet Response (Definition 1) | 156 of 168 | 214 of 239 | 407 | NCT00508820 | Trial comparisons |
| Romiplostim Cohort 1 vs Romiplostim Cohort 2: serious adverse events | 61 of 168 | 61 of 239 | 407 | NCT00508820 | Trial comparisons |
| AMG 531 vs Standard of Care: serious adverse events | 36 of 156 | 28 of 73 | 229 | NCT00415532 | Trial comparisons |
| Efgartigimod PH20 SC vs Placebo PH20 SC: deaths from any cause | 1 of 137 | 0 of 70 | 207 | NCT04687072 | Trial comparisons |
| Efgartigimod PH20 SC vs Placebo PH20 SC: serious adverse events | 14 of 137 | 10 of 70 | 207 | NCT04687072 | Trial comparisons |
| Eltrombopag 50 mg QD vs Placebo: serious adverse events | 16 of 135 | 11 of 61 | 196 | NCT00370331 | Trial comparisons |
| Eltrombopag vs Placebo: deaths from any cause | 0 of 104 | 3 of 51 | 155 | NCT01762761 | Trial comparisons |
| Eltrombopag vs Placebo: serious adverse events | 33 of 104 | 17 of 51 | 155 | NCT01762761 | Trial comparisons |
| Eltrombopag vs Placebo: Number of Participants (Responders) Achieving a Platelet Count >=50×10^9/L After the First 6 Weeks of Stage 1 | 60 of 104 | 3 of 50 | 154 | NCT01762761 | Trial comparisons |
| Eltrombopag vs Placebo: Number of Participants Achieving a Platelet Count >=50×10^9/L at Least Once During the First 6 Weeks of Stage 1 | 80 of 104 | 9 of 50 | 154 | NCT01762761 | Trial comparisons |
| Efgartigimod vs Placebo: deaths from any cause | 0 of 86 | 0 of 45 | 131 | NCT04188379 | Trial comparisons |
| Efgartigimod vs Placebo: serious adverse events | 7 of 86 | 7 of 45 | 131 | NCT04188379 | Trial comparisons |
| Experimental: Eltrombopag vs Comparator: Standard Therapy: Proportion of Patients With a Platelet Response | 52 of 78 | 14 of 40 | 118 | NCT03939637 | Trial comparisons |
| Experimental: Eltrombopag vs Comparator: Standard Therapy: Cumulative Number of Rescue Therapies Required | 13 of 78 | 15 of 39 | 117 | NCT03939637 | Trial comparisons |
| Experimental: Eltrombopag vs Comparator: Standard Therapy: deaths from any cause | 0 of 78 | 0 of 39 | 117 | NCT03939637 | Trial comparisons |
| Experimental: Eltrombopag vs Comparator: Standard Therapy: serious adverse events | 6 of 78 | 3 of 39 | 117 | NCT03939637 | Trial comparisons |
| Part 1 (Randomized Period) - Eltrombopag vs Part 1 (Randomized Period)-Placebo: Number of Participants Achieving a Platelet Count >=50 Gi/L at Any Time During the First 12 Weeks of Part 1 | 47 of 63 | 6 of 29 | 92 | NCT01520909 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0008558/comparisons